References:
1. Chen S, Zhang Z, Yang J, et al. Fangcang shelter hospitals: a novel
concept for responding to public health emergencies. Lancet.2020.
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
3. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral
shedding in adult patients hospitalized with influenza. J Infect
Dis. 2009;200(4):492-500.
4. Wang Y, Guo Q, Yan Z, et al. Factors Associated With Prolonged Viral
Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.J Infect Dis. 2018;217(11):1708-1717.
5. Chen R, Zou Q, Xie G, et al. Characterization of viral genomic
mutations in novel influenza A (H7N9)-infected patients: the association
between oseltamivir-resistant variants and viral shedding duration.Virus Genes. 2019;55(5):592-599.
6. Fielding JE, Kelly HA, Mercer GN, Glass K. Systematic review of
influenza A(H1N1)pdm09 virus shedding: duration is affected by severity,
but not age. Influenza Other Respir Viruses. 2014;8(2):142-150.
7. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human
influenza A (H5N1) is associated with high viral load and
hypercytokinemia. Nature Medicine. 2006;12(10):1203-1207.
8. Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract
and beyond: a molecular pathology study. Lancet.2007;370(9593):1137-1145.
9. Fielding JE, Kelly HA, Mercer GN, Glass K. Systematic review of
influenza A(H1N1)pdm09 virus shedding: duration is affected by severity,
but not age. Influenza and Other Respiratory Viruses.2014;8(2):142-150.
10. Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S,
Ciccozzi M. COVID-2019: The role of the nsp2 and nsp3 in its
pathogenesis. J Med Virol. 2020.
11. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of
SARS-CoV-2. National Science Review. 2020.
12. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus
Disease 2019 in China. N Engl J Med. 2020.
13. Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and
outcomes of hospitalised patients with COVID-19 treated in Hubei
(epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of
China. Eur Respir J. 2020.
14. Cao X. COVID-19: immunopathology and its implications for therapy.Nat Rev Immunol. 2020.
15. Chen G, Wu D, Guo W, et al. Clinical and immunological features of
severe and moderate coronavirus disease 2019. The Journal of
Clinical Investigation. 2020;130(5).
16. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral
RNA shedding in patients with COVID-19. Clinical Infectious
Diseases. 2020.
Tables :